Sarepta Updates its Potential Blockbuster

Before you go, we thought you'd like these...
Before you go close icon

Shares of Sarepta were trading down 5%, after the company released its 62-week look at its Duchenne muscular dystrophy drug Eteplirsen. The company's 48-week look at the drug produced results that indicated the drug may revolutionize the way we treat the disease, as it not only slowed DMD's progression, it actually lengthened the distance patients were able to walk. The 62-week results were also good, but, perhaps, the market was expecting a miracle after what it saw at the 48-week mark. Sarepta stock jumped up 26% in November for a colossal 550% for the year.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Sarepta Updates its Potential Blockbuster originally appeared on

David Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners